Log In
BCIQ
Print this Print this
 

STI-A1110

  Manage Alerts
Collapse Summary General Information
Company Sorrento Therapeutics Inc.
DescriptionAnti-programmed cell death 1 (PD-1; PDCD1; CD279) mAb
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerServier

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$976.9M

$27.6M

$949.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/11/2016

$976.9M

$27.6M

$949.3M

Get a free BioCentury trial today